As the orphan drug market grows exponentially, everyone is looking into China and whether the country is prepared to provide access for therapies to rare disease patients. Pharma companies like Genzyme have made strong efforts to introduce one of its orphan drugs in China and into the healthcare system in force.
China has reached a remarkable achievement in the past decade in becoming a medical research powerhouse, with significant increase in the number of scientific outputs in the rare disease space as well. However, the country’s growing role in rare medical research will only increase if they are able to translate research into orphan drug development or some form of healthcare innovation.
What is truly necessary is a system worked out for China, with distinguished scientists in bioscience and medicine area who are able to translate their findings into genure outcomes. That also comes from executive power and engagement and it is believed that the government will set an united patients advocacy program under the moderation of ministry of health this year. This shows that what is truly important is the innovation in the whole healthcare system.
China’s Ministry of Health representative, Mrs. Ren Yufu will participate at the World Orphan Drug Congress USA 2013 next April in DC and will address the potential reform of the country’s healthcare system that will benefit orphan drug development and access in the next most important orphan drug market in the world.
Read the full article here.